- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2011.
- Why 3/10
- Nulojix is an already-approved, marketed drug with no pending regulatory decision (PDUFA, AdComm, or pivotal readout) scheduled in the next 12 months. It is a niche product grouped under "Other Growth Brands" within BMS's $48B+ annual revenue, and BMS does not break out its revenue. Therefore, impactScore is 3 per the rubric: approved and commercializing with no binary catalyst, a small part of a large pipeline.
Nulojix has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. Watch for any label expansion into pediatric kidney transplant or heart transplant (Phase 2 data ongoing), but neither represents a near-term binary event. The main long-term risk is biosimilar entry as patents expire, with Alphamab Oncology's KN019 (belatacept biosimilar) in Chinese clinical development.
Price Chart
Executive Summary
Nulojix (belatacept) is an FDA-approved biologic from Bristol Myers Squibb (BMY) used to prevent organ rejection in adult kidney transplant recipients. Approved in June 2011, it is a selective T-cell costimulation blocker that offers a kidney-friendly alternative to calcineurin inhibitors. However, Nulojix is a niche product within BMS's massive $48B+ annual revenue base; the company does not break out its revenue separately, grouping it under "Other Growth Brands." With no pending regulatory decisions or near-term pivotal readouts, Nulojix is a mature, commercial-stage asset with limited binary catalyst potential for BMY shares.
How It Works
Nulojix is a biologic drug (a lab-made protein) that suppresses the immune system to prevent the body from attacking a transplanted kidney. It works by blocking a key activation signal that T-cells (a type of white blood cell) need to launch an immune response against the donor organ. This makes it an alternative to older immunosuppressants that can damage the kidneys over time.
Trial Status
Nulojix was approved by the FDA in June 2011 based on two Phase 3 trials (BENEFIT and BENEFIT-EXT) comparing it to cyclosporine in adult kidney transplant recipients. It is a marketed product. A Phase 2 investigator-sponsored trial (NCT06478017) is evaluating belatacept in heart transplantation, and pediatric data have been published in medical journals, but no pivotal registrational trials for label expansion are currently listed.
The Two-Sided Case
Upcoming Catalysts
- No scheduled PDUFA dates or pivotal readouts for Nulojix in the next 12 months.
- Ongoing Phase 2 heart transplant data (NCT06478017) could inform future label expansion but is not a near-term binary catalyst.
- Biosimilar competition: Alphamab Oncology's KN019 (belatacept biosimilar) is in clinical development in China but not yet filed in the US.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report